Nacuity Pharmaceuticals, Inc

Nacuity Pharmaceuticals is a clinical-stage leader in innovative treatments for oxidative stress. The company’s powerful, targeted therapies aim to stop oxidative tissue damage, a driver of many blinding eye diseases and a broad spectrum of serious chronic conditions. Powered by key backing and technical support from the world’s leading private funders of retinal disease research, Foundation Fighting Blindness and RD Fund, Nacuity is pursuing near-term proof-of-concept data in several of its highly differentiated clinical programs, including retinitis pigmentosa, cataract, and cystinosis, with the potential to be first-of-a-kind therapies and gateways to wider applications.